Correlation Between Incyte and ProQR Therapeutics

Can any of the company-specific risk be diversified away by investing in both Incyte and ProQR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Incyte and ProQR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Incyte and ProQR Therapeutics BV, you can compare the effects of market volatilities on Incyte and ProQR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Incyte with a short position of ProQR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Incyte and ProQR Therapeutics.

Diversification Opportunities for Incyte and ProQR Therapeutics

0.68

Correlation Coefficient

Incyte  ProQR Therapeutics

Poor diversification

The 3 months correlation between Incyte and ProQR is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Incyte and ProQR Therapeutics BV in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ProQR Therapeutics and Incyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Incyte are associated (or correlated) with ProQR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ProQR Therapeutics has no effect on the direction of Incyte i.e., Incyte and ProQR Therapeutics go up and down completely randomly.

Pair Corralation between Incyte and ProQR Therapeutics

Given the investment horizon of 90 days Incyte is expected to generate 7.48 times less return on investment than ProQR Therapeutics. But when comparing it to its historical volatility, Incyte is 6.29 times less risky than ProQR Therapeutics. It trades about 0.09 of its potential returns per unit of risk. ProQR Therapeutics BV is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  192.00  in ProQR Therapeutics BV on August 31, 2024 and sell it today you would earn a total of  175.00  from holding ProQR Therapeutics BV or generate 91.15% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Incyte  vs.  ProQR Therapeutics BV

Incyte

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Incyte are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Incyte showed solid returns over the last few months and may actually be approaching a breakup point.

ProQR Therapeutics

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in ProQR Therapeutics BV are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, ProQR Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Incyte and ProQR Therapeutics

The main advantage of trading using opposite Incyte and ProQR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Incyte position performs unexpectedly, ProQR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will offset losses from the drop in ProQR Therapeutics' long position.

The idea behind Incyte and ProQR Therapeutics BV pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.